# p-ERα (Ser 167): sc-101676



The Power to Question

## **BACKGROUND**

Estrogen receptor  $\alpha$  (ER $\alpha$ , ER, ESR, ESRA, Era, NR3A1, estrogen receptor 1) is a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding and activation of transcription. Alternative splicing results in several ER $\alpha$  mRNA transcripts, which differ primarily in their 5' untranslated regions. ER $\alpha$  undergoes phosphorylation in response to estradiol binding. Human ER $\alpha$  is predominately phosphorylated on Ser 118 and, to a lesser extent, on Ser 104 and Ser 106. In response to activation of the mitogen-activated protein kinase pathway, phosphorylation occurs on Ser 118 and Ser 167. These serine residues are all located within the activation function 1 region of the N-terminal domain of ER $\alpha$ . In contrast, activation of protein kinase A increases the phosphorylation of Ser 236, which is located in the DNA-binding domain. Src kinase-dependent Tyr 537 phosphorylation may enhance estrogen binding to ER $\alpha$ . Mutation of Tyr 537 of the human ER $\alpha$  produces receptors having a range of constitutive activity.

# **REFERENCES**

- Arnold, S.F., et al. 1995. Phosphorylation of Tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J. Biol. Chem. 270: 30205-30212.
- Weis, K.E., et al. 1996. Constitutively active human estrogen receptors containing amino acid substitutions for Tyrosine 537 in the receptor protein. Mol. Endocrinol. 10: 1388-1398.

# **CHROMOSOMAL LOCATION**

Genetic locus: ESR1 (human) mapping to 6q25.1; Esr1 (mouse) mapping to 10 A1.

## **SOURCE**

p-ER $\alpha$  (Ser 167) is a rabbit polyclonal antibody raised against a short amino acid sequence containing Ser 167 phosphorylated ER $\alpha$  of human origin.

# **PRODUCT**

Each vial contains 100  $\mu g$  lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

#### **APPLICATIONS**

p-ER $\alpha$  (Ser 167) is recommended for detection of Ser 167 phosphorylated ER $\alpha$  of human origin and correspondingly phosphorylated Ser 171 of mouse origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).


Suitable for use as control antibody for ER $\alpha$  siRNA (h): sc-29305, ER $\alpha$  siRNA (m): sc-29306, ER $\alpha$  shRNA Plasmid (h): sc-29305-SH, ER $\alpha$  shRNA Plasmid (m): sc-29306-SH, ER $\alpha$  shRNA (h) Lentiviral Particles: sc-29305-V and ER $\alpha$  shRNA (m) Lentiviral Particles: sc-29306-V.


Molecular Weight of p-ERα: 66 kDa.

#### **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto B Blocking Reagent: sc-2335 (use 50 mM NaF, sc-24988, as diluent), Western Blotting Luminol Reagent: sc-2048 and Lambda Phosphatase: sc-200312A. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 4) Immunohistochemistry: use ImmunoCruz™: sc-2051 or ABC: sc-2018 rabbit IgG Staining Systems.

## **DATA**





p-ER $\alpha$  (Ser 167): sc-101676. Western blot analysis of phosphorylated ER $\alpha$  expression in untreated (**A**) and EGF-treated (**B**) MCF7 whole cell lysates.

p-ERa (Ser 167): sc-101676. Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing nuclear localization

### **SELECT PRODUCT CITATIONS**

- 1. Molitoris, K.H., et al. 2009. Inhibition of oxygen-induced hypoxia-inducible factor- $1\alpha$  degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells *in vitro*. Endocrinology 150: 5405-5414.
- 2. Guo, J.P., et al. 2010. IKK $\epsilon$  phosphorylation of estrogen receptor  $\alpha$  Ser-167 and contribution to tamoxifen resistance in breast cancer. J. Biol. Chem. 285: 3676-3684
- Clark, S., et al. 2014. Estrogen receptor-mediated transcription involves the activation of multiple kinase pathways in neuroblastoma cells. J. Steroid Biochem. Mol. Biol. 139: 45-53.

### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

# **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com